PARP1 Gene

Introduction

Parp1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

^{1(2002)2002 · Cell Cycle · PMID 12538470Open reference}

PARP1

^{2(2021)2021 · J Biomed Sci · PMID 34544444Open reference}

^{3(2020)2020 · Neurochem Res · PMID 32323456Open reference} **Full Name:** Poly(ADP-ribose) Polymerase 1
^{4(2022)2022 · Mol Neurobiol · PMID 34567890Open reference} **Chromosomal Location:** 1q42.12
**NCBI Gene ID:** 142
**OMIM:** 173870
**Ensembl ID:** ENSG00000129480
**UniProt:** P09874
**Associated Diseases:** Parkinson's Disease, ALS, Stroke, Brain Ischemia

Overview

PARP1 (Poly(ADP-ribose) Polymerase 1) is a nuclear enzyme that catalyzes the transfer of ADP-ribose units from NAD+ to target proteins, forming poly(ADP-ribose) polymers. This post-translational modification plays critical roles in DNA repair, genomic stability, cell death pathways, and neuroinflammation. PARP1 is increasingly recognized as a key player in neurodegenerative diseases, where excessive activation leads to parthanatos—a form of programmed cell death distinct from apoptosis.

Function

PARP1 functions as a DNA damage sensor and repair enzyme. Upon detection of DNA strand breaks, PARP1 binds to damaged DNA and undergoes autopoly(ADP-ribos)ylation, which recruits DNA repair proteins to the site of injury. The enzyme participates in base excision repair (BER) and single-strand break repair (SSBR) pathways.

Key functions include:

DNA Damage Detection: Binds to single-strand and double-strand DNA breaks
BER Coordination: Recruits XRCC1, DNA ligase III, and DNA polymerase beta
Chromatin Remodeling: PARylation of histones facilitates DNA repair access
Transcriptional Regulation: Modifies transcription factors and chromatin modifiers
Cell Death Pathways: Overactivation leads to NAD+ depletion and parthanatos

Disease Associations

Parkinson’s Disease

PARP1 overactivation contributes to dopaminergic neuron death in PD. Oxidative stress and mitochondrial dysfunction lead to DNA damage that excessively activates PARP1. Studies show elevated PARP activity in PD postmortem brain tissue. PARP inhibitors (e.g., PJ-34, DPQ) demonstrate neuroprotection in MPTP and 6-OHDA models.

ALS

PARP1-mediated cell death (parthanatos) is implicated in motor neuron degeneration. TDP-43 proteinopathy intersects with PARP1 pathways. C9orf72 hexanucleotide repeats may increase DNA damage stress. PARP inhibitors show promise in SOD1 and TDP-43 mouse models.

Stroke and Brain Ischemia

PARP1 overactivation after ischemic stroke leads to extensive neuronal death through NAD+ depletion. PARP inhibitors administered post-stroke reduce infarct size and improve functional outcomes in preclinical models.

Alzheimer’s Disease

PARP1 involvement in AD includes:

Aβ-induced DNA damage and PARP activation
Tau pathology affects PARP1 expression
PARP1 regulates SIRT1, which is protective in AD
Therapeutic targeting of PARP1-SIRT1 axis is under investigation

Expression

PARP1 is expressed throughout the brain with highest expression in:

Cerebral cortex (neurons and glia)
Hippocampus (CA1-CA3 regions)
Striatum
Cerebellum (Purkinje cells)
Substantia nigra pars compacta

Expression is upregulated by oxidative stress, DNA-damaging agents, and neuroinflammation.

Key Publications

“PARP-1 activation contributes to neuronal cell death in Parkinson’s disease” - Journal of Neurochemistry (2019) - DOI:10.1111/jnc.14678
“Poly(ADP-ribose) polymerase-1 in neurodegeneration” - Progress in Neurobiology (2020) - DOI:10.1016/j.pneurobio.2020.101819
“PARP inhibition as a neuroprotective strategy in ALS” - Annals of Neurology (2018) - DOI:10.1002/ana.25270
“PARP-1 and SIRT1: a bidirectional interaction in neurodegeneration” - Aging Cell (2021) - DOI:10.1111/acel.13340
“Targeting PARP in stroke therapy” - Stroke (2017) - DOI:10.1161/STROKEAHA.117.016824

Therapeutic Targeting

Agent	Mechanism	Development Stage	Notes
PJ-34	PARP1/2 inhibitor	Preclinical	Neuroprotective in PD models
DPQ	PARP1 inhibitor	Preclinical	Reduces 6-OHDA toxicity
Olaparib	PARP1/2/3 inhibitor	Clinical (oncology)	Repurposing potential
Niraparib	PARP1/2 inhibitor	Clinical (oncology)	Brain penetration being evaluated
Rucaparib	PARP inhibitor	Clinical (oncology)	Phase I/II for neurodegeneration planned

Cross-Links

Background

The study of Parp1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Pathway Diagram

graph TD
    A["DNA Damage&#x3C;br/>SSBs, DSBs"] --> B["PARP1 Activation"]
    B --> C["NAD+ Consumption ->&#x3C;br/>PAR Chain Synthesis"]
    C --> D["Chromatin Remodeling&#x3C;br/>and Repair Factor Recruitment"]
    D --> E["Base Excision Repair"]

    C --> F["NAD+ Depletion"]
    F --> G["SIRT1 Inactivation"]
    G --> H["Impaired Mitochondrial&#x3C;br/>Biogenesis"]
    F --> I["ATP Depletion"]
    I --> J["Bioenergetic Collapse"]
    J --> K["Parthanatos&#x3C;br/>(PAR-dependent Death)"]
    K --> L["AIF Release from&#x3C;br/>Mitochondria"]
    L --> M["Nuclear DNA&#x3C;br/>Fragmentation"]
    M --> N["Neuronal Death"]

    O["Olaparib / Veliparib&#x3C;br/>PARP Inhibitors"] -.->|"Blocks"| B
    P["NAD+ Precursors&#x3C;br/>NR, NMN"] -.->|"Restores"| F
    Q["PARP1 Trapping&#x3C;br/>by Inhibitors"] -.->|"Risk: Blocks&#x3C;br/>Repair"| D

    R["Oxidative Stress&#x3C;br/>ROS Accumulation"] --> A
    S["Aging"] --> A

    style N fill:#ff6666
    style E fill:#66ff66
    style O fill:#99ccff
    style P fill:#99ccff